XLO insider buying and SEC filings, explained
Xilio Therapeutics, Inc. · CIK 1840233
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$44K
Insiders who bought
1
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$6K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Mar 26, 2026 | Purchase (code P) | James Samuel Shannon (Director) bought 5,000 shares at about $8.79 ($44K), reported as a purchase (code P). Holdings up 100% to 10,000 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 30, 2026 |
| Feb 13, 2026 | Other purchase | GILEAD SCIENCES, INC. (10% owner) bought 3,739,000 Prefunded Warrants (right to buy) at $0.5300 ($2.0M), reported as a purchase (code P). Holdings up 10% to 40,384,266 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 17, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Kevin M. Brennan (SVP, Finance and Accounting) sold 1,826 shares at $0.6400 ($1K), marked as a 10b5-1 plan trade. Holdings down 22% to 6,371 shares. | SEC filing Filed Jan 5, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Christopher James Frankenfield (CFO) sold 7,030 shares at $0.6400 ($4K), marked as a 10b5-1 plan trade. Holdings down 22% to 24,766 shares. | SEC filing Filed Jan 5, 2026 |
18 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow XLO in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.